Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular Pathways

Targeting TRAIL Agonistic Receptors for Cancer Therapy

Carmelo Carlo-Stella, Cristiana Lavazza, Alberta Locatelli, Lucia Viganò, Alessandro M. Gianni and Luca Gianni
Carmelo Carlo-Stella
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristiana Lavazza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberta Locatelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucia Viganò
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro M. Gianni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Gianni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-06-2774 Published April 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Crosstalk between apoptosis signaling pathways following activation of death receptors. Death receptors trigger the cell-intrinsic pathway by activation of caspase-8 and caspase-10. Cleaved BID interacts with Bax and Bak, which in turn, activate caspase-9 and caspase-3, resulting in apoptosis induction through the cell-extrinsic pathway. In type I cells, death-receptor engagement of the cell-extrinsic pathway is sufficient for commitment to apoptotic death. In type II cells, commitment to apoptosis requires the amplification of the death-receptor signal by the cell-intrinsic pathway. Because death-receptor targeting and conventional agents induce tumor cell apoptosis through different signaling pathways, combinations of the two approaches might facilitate the killing of tumor cells that resist death induction through either one of the pathways.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Therapeutic approaches to death receptor activation. TRAIL-R1 and TRAIL-R2 can be engaged by soluble TRAIL as well as the membrane-bound form of the ligand. Agonistic antibodies selectively bind either TRAIL-R1 or TRAIL-R2.

PreviousNext
Back to top
Clinical Cancer Research: 13 (8)
April 2007
Volume 13, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeting TRAIL Agonistic Receptors for Cancer Therapy
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Targeting TRAIL Agonistic Receptors for Cancer Therapy
Carmelo Carlo-Stella, Cristiana Lavazza, Alberta Locatelli, Lucia Viganò, Alessandro M. Gianni and Luca Gianni
Clin Cancer Res April 15 2007 (13) (8) 2313-2317; DOI: 10.1158/1078-0432.CCR-06-2774

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeting TRAIL Agonistic Receptors for Cancer Therapy
Carmelo Carlo-Stella, Cristiana Lavazza, Alberta Locatelli, Lucia Viganò, Alessandro M. Gianni and Luca Gianni
Clin Cancer Res April 15 2007 (13) (8) 2313-2317; DOI: 10.1158/1078-0432.CCR-06-2774
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Background
    • TRAIL-Induced Apoptosis Signaling
    • Clinical-Translational Advances
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Targeting of the Liver Microenvironment
  • Targeting the Protein Kinase Wee1 in Cancer
  • Metabolic Control of Histone Methylation and Gene Expression
Show more Molecular Pathways
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement